A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
REGULATORY
Xocova Approval Meaningful, but Careful Use Should Continue: Minister
Japanese health minister Keizo Takemi on March 5 stressed the significance of standard approval granted the same day to Shionogi’s COVID-19 antiviral Xocova (ensitrelvir), while calling on healthcare providers to retain their caution in prescribing the drug. “The reaffirmation of…
To read the full story
Related Article
- Shionogi’s COVID Pill Xocova Lands Standard Approval in Japan
March 5, 2024
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
REGULATORY
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
- Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…